Cardiovascular Disease

Donna Ryan, MD, discusses the most significant clinical trials published this year in the field of obesity medicine.

Your daily dose of the clinical news you may have missed.

Which state retains the most medical residents? Or has the lowest cancer rate? Answers and more insights from a nationwide analysis, here.

Your daily dose of the clinical news you may have missed.

ESC 2024: Findings from the FINEARTS-HF clinical trial provide the first definite evidence that an MRA can be beneficial in patients with HFmrEF/HFpEF.

ESC 2024: Cannabis, opioid, and MDMA use were most strongly tied to cardiovascular event risk, according to a new study.

Your daily dose of the clinical news you may have missed.

In secondary CVD prevention, low/moderate-dose statins plus ezetimibe were superior to high-dose statin for reducing biomarkers, myalgias but did not reduce MACE.

The sGC activator represents a novel approach to modulating the nitric oxide-soluble sGC-cyclic guanosine monophosphate pathway.

Anila Chadha, MD, talks to Patient Care about how antiobesity medications can aid in reducing CVD risk in patients with obesity.

Anila Chadha, MD, highlights key preventive strategies to reduce CVD risk in patients with obesity and how to tailor them to address individual patient needs.

White coat and masked hypertension can be elusive and dangerous. Click through a topline look at recommendations from the 2017 ACC/AHA hypertension guidelines.

Conversely, greater intake of animal-based fat was associated with an increased risk of overall and CVD mortality, authors reported.

Your daily dose of the clinical news you may have missed.

Based on guidance from the American Society of Preventive Cardiology, this topline summarizes risk factors and interventions to reduce the risk of major adverse CV events.

Participants with AF who used wearable devices reported higher anxiety levels and increased health care usage than nonusers, according to a new study.

Your daily dose of the clinical news you may have missed.

Adherence to Mediterranean diet-based interventions was associated with reductions in BP, triglycerides, total cholesterol, and LDL-C, as well as increases in HDL-C among children and adolescents.

Adiposity before age 60 to 64 years, beginning as early as age 20 years, was associated with adverse cardiac structure and function not explained by current BMI.

Your daily dose of the clinical news you may have missed.

The risk for developing CVD and T2D was highest among individuals who frequently experienced the behavior in the workplace, according to new study.

Your daily dose of the clinical news you may have missed.

ADA 2024. Semaglutide benefits were observed for adults with type 2 diabetes and chronic kidney disease whether or not they used SGLT-2 inhibitors, according to an analysis of FLOW trial data.

Your daily dose of the clinical news you may have missed.

Between 2000 and 2022, there were nearly 800 000 excess CV deaths among Black Americans and 24 million additional years of life lost, researchers report.

Your daily dose of the clinical news you may have missed.

In contrast, men did not face the same increased risk of cerebrovascular disease later in life, reported authors of a new study.

Your daily dose of the clinical news you may have missed.

ENDO 2024. New findings suggest GLP-1RAs and SGLT-2is may be more beneficial than other diabetes agents for patients with T2D and MASLD.

Plozasiran, in the phase 2b MUIR trial, significantly reduced triglyceride and triglyceride rich lipoprotein levels through targeted action against APOC3.